-
春雷霉素鹽酸鹽一水合物
- names:
Kasugamycin hydrochloride hydrate
- CAS號:
200132-83-8
MDL Number: MFCD00149375 - MF(分子式): C14H28ClN3O10 MW(分子量): 433.84
- EINECS: Reaxys Number:
- Pubchem ID:57369825 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (¥) | 現(xiàn)價(¥) | 特價(¥) | 庫存描述 | 數(shù)量 | 總計 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000177-500mg | 500mg | 97.91% | ¥ 487.50 | ¥ 487.50 | 2-3天 | ¥ 0.00 |
- 大包裝詢價 提供各種包裝,敬請垂詢
- 收藏商品 商品點(diǎn)評 加入購物車 立即購買
| 中文別名 | 春雷霉素鹽酸鹽一水合物(00132-83-8);鹽酸春日霉素水合物; 2-氨基-2-[((2R,3S,5S,6R)-5-氨基-2-甲基-6-[(2S,3S,5S,6R)-2,3,4,5,6-五羥基環(huán)己基]氧雜-3-基]亞氨基乙酸;水合物;鹽酸鹽;UNII-5A9BN7V7QL;5A9BN7V7QL;SCHEMBL69506; |
| 英文別名 | Kasugamycin hydrochloride hydrate(00132-83-8);,Ksg hydrochloride hydrate;2-amino-2-[(2R,3S,5S,6R)-5-amino-2-methyl-6-[(2S,3S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyoxan-3-yl]iminoacetic acid;hydrate;hydrochloride;UNII-5A9BN7V7QL;5A9BN7V7QL;SCHEMBL69506; |
| CAS號 | 200132-83-8 |
| Inchi | InChI=1S/C14H25N3O9.ClH.H2O/c1-3-5(17-12(16)13(23)24)2-4(15)14(25-3)26-11-9(21)7(19)6(18)8(20)10(11)22;;/h3-11,14,18-22H,2,15H2,1H3,(H2,16,17)(H,23,24);1H;1H2/t3-,4+,5+,6-,7+,8+,9-,10+,11+,14-;;/m1../s1 |
| InchiKey | URDOPMVCASNBEZ-IYWSOWMLSA-N |
| 分子式 Formula | C14H28ClN3O10 |
| 分子量 Molecular Weight | 433.84 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度14.33 mg/mL(33.03 mM;Need ultrasonic and warming) |
| 性狀 | 無色透明液體 |
| 儲藏條件 Storage conditions | 存放在陰涼干燥處,短期(數(shù)天至數(shù)周)在0-4℃,長期(數(shù)月至數(shù)年)在-35℃。 |
春雷霉素鹽酸鹽一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)解毒劑和緊急治療
Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
春雷霉素鹽酸鹽一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)實(shí)驗(yàn)注意事項(xiàng):
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲,并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:春雷霉素鹽酸鹽一水合物試劑,春雷霉素鹽酸鹽一水合物雜質(zhì),春雷霉素鹽酸鹽一水合物中間體,春雷霉素鹽酸鹽一水合物密度,春雷霉素鹽酸鹽一水合物合成,春雷霉素鹽酸鹽一水合物溶解度,春雷霉素鹽酸鹽一水合物旋光度,春雷霉素鹽酸鹽一水合物閃點(diǎn),春雷霉素鹽酸鹽一水合物熔點(diǎn),春雷霉素鹽酸鹽一水合物購買,
| 產(chǎn)品說明 | 春雷霉素鹽酸鹽一水合物(00132-83-8,Ksg hydrochloride hydrate)是結(jié)合30S和70S核糖體但不分離50S亞基的抗生素。 |
| Introduction | 春雷霉素鹽酸鹽一水合物(00132-83-8,Ksg hydrochloride hydrate)is an antibiotic which binds both the 30S and 70S ribosome but not isolated 50S subunits. |
| Application1 | 鹽酸春日霉素水合物(Ksg鹽酸水合物)模擬mRNA核苷酸以破壞tRNA結(jié)合并抑制規(guī)范翻譯起始 |
| Application2 | Kasugamycin hydrochloride hydrate mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. |
| Application3 |
春雷霉素鹽酸鹽一水合物是一種氨基糖苷類抗生素,春雷霉素鹽酸鹽一水合物通過與30S核糖體亞基相互作用來抑制蛋白質(zhì)合成。春雷霉素鹽酸鹽一水合物抑制蛋白質(zhì)合成的機(jī)制似乎與其他氨基糖苷類(如鏈霉素,卡那霉素)不同。
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食入,做好安全防護(hù) |
雷霉素鹽酸鹽一水合物(00132-83-8,Kasugamycin hydrochloride hydrate,Ksg hydrochloride hydrate)危害處理:
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.
| Schluenzen F, et al. The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat Struct Mol Biol. 2006 Oct;13(10):871-8. |
| Schuwirth BS, et al. Structural analysis of kasugamycin inhibition of translation. Nat Struct Mol Biol. 2006 Oct;13(10):879-86. |
1、Structural analysis of kasugamycin inhibition of translation
Barbara S Schuwirth 1, J Michael Day, Cathy W Hau, Gary R Janssen, Albert E Dahlberg, Jamie H Doudna Cate, Antón Vila-Sanjurjo
Abstract The prokaryotic ribosome is an important target of antibiotic action. We determined the X-ray structure of the aminoglycoside kasugamycin (Ksg) in complex with the Escherichia coli 70S ribosome at 3.5-A resolution. The structure reveals that the drug binds within the messenger RNA channel of the 30S subunit between the universally conserved G926 and A794 nucleotides in 16S ribosomal RNA, which are sites of Ksg resistance. To our surprise, Ksg resistance mutations do not inhibit binding of the drug to the ribosome. The present structural and biochemical results indicate that inhibition by Ksg and Ksg resistance are closely linked to the structure of the mRNA at the junction of the peptidyl-tRNA and exit-tRNA sites (P and E sites).
2、The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation
Frank Schluenzen 1, Chie Takemoto, Daniel N Wilson, Tatsuya Kaminishi, Joerg M Harms, Kyoko Hanawa-Suetsugu, Witold Szaflarski, Masahito Kawazoe, Mikako Shirouzu, Knud H Nierhaus, Shigeyuki Yokoyama, Paola Fucini
Abstract Kasugamycin (Ksg) specifically inhibits translation initiation of canonical but not of leaderless messenger RNAs. Ksg inhibition is thought to occur by direct competition with initiator transfer RNA. The 3.35-A structure of Ksg bound to the 30S ribosomal subunit presented here provides a structural description of two Ksg-binding sites as well as a basis for understanding Ksg resistance. Notably, neither binding position overlaps with P-site tRNA; instead, Ksg mimics codon nucleotides at the P and E sites by binding within the path of the mRNA. Coupled with biochemical experiments, our results suggest that Ksg indirectly inhibits P-site tRNA binding through perturbation of the mRNA-tRNA codon-anticodon interaction during 30S canonical initiation. In contrast, for 70S-type initiation on leaderless mRNA, the overlap between mRNA and Ksg is reduced and the binding of tRNA is further stabilized by the presence of the 50S subunit, minimizing Ksg efficacy.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色,是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長,主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來,Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個重要因素是:微流控...
2023/7/27 12:44:28
驗(yàn)動物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽(K+)設(shè)計用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問題
牛血清白蛋白(BSA)常見問題:牛血清白蛋白(BSA)在實(shí)驗(yàn)室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購物車 


